Progress towards new treatments for human African trypanosomiasis

Trypanosomes and Trypanosomiasis

Volumn , Issue , 2014, Pages 217-238

  Garcia Salcedo, Jose A ^a   Munday, Jane C ^b,c   Unciti Broceta, Juan D ^a   De Koning, Harry P ^b  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84912073239     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-1556-5_9     Document Type: Chapter

References (145)

1. Abdulla MH, OBrien T, Mackey ZB et al (2008) RNA interference of Trypanosoma brucei cathepsin B and L affects disease progression in a mouse model. PLoS Negl Trop Dis 2:e298
2. Allen CL, Goulding D, Field MC (2003) Clathrin-mediated endocytosis is essential in Trypanosoma brucei. EMBO J 22:4991-5002
3. Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, Leung K-F, Turner DJ, Field MC, Berriman M, Horn D (2012) High-throughput decoding of anti-trypanosomal drug efficacy and resistance. Nature 482:232-236
4. Ang KKH, Ratnam J, Gut J et al (2011) Mining a cathepsin inhibitor library for new antiparasitic drug leads. PLoS Negl Trop Dis 5:e1023
5. Atougia JLM, Kennedy PGE (2000) Neurological aspects of human trypanosomiasis. In: Le D, Kennedy PGE (eds) Infectious diseases of the nervous system. Butterowrth-Heinemann, Oxford, pp 321-372
6. Baker N, Alsford S, Horn D (2011) Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol Biochem Parasitol 176:55-57
7. Baker N, Glover L, Munday JC et al (2012) Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc Natl Acad Sci USA 109:10996-11001
8. Baker N, de Koning HP, Mäser P, Horn D (2013) Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol 29:110-118
9. Baral TN, Magez S, Stijlemans B et al (2006) Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med 12:580-584
10. Barquilla A, Crespo JL, Navarro M (2008) Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation. Proc Natl Acad Sci USA 105:14579-14584
11. Barrett MP, Croft SL (2012) Management of trypanosomiasis and leishmaniasis. Br Med Bull 104:175-196
12. Bassarak B, Uzcátegui NL, Schönfeld C, Duszenko M (2011) Functional characterization of three aquaglyceroporins from Trypanosoma brucei in osmoregulation and glycerol transport. Cell Physiol Biochem 27:411-420
13. Basselin M, Denise H, Coombs GH, Barrett MP (2002) Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob Agents Chemother 46:3731-3738
14. Beitz E (2005) Aquaporins from pathogenic protozoan parasites: structure, function and potential for chemotherapy. Biol Cell 97:373-383
15. Beitz E, Wu B, Holm LM, Schultz JE, Zeuthen T (2006) Point mutations in the aromatic/arginine region in aquaporin 1 allow passage of urea, glycerol, ammonia, and protons. Proc Natl Acad Sci USA 103:269-274
16. Bhatnagar RS, Futterer K, Waksman G, Gordon JI (1999) The structure of myristoyl-CoA:protein N-myristoyltransferase. Biochim Biophys Acta 1441:162-172
17. Bosch F, Rosich L (2008) The contributions of Paul Ehrlich to Pharmacology: a tribute on the occasion of the centenary of his Nobel prize. Pharmacology 82:171-179
18. Bowyer PW, Tate EW, Leatherbarrow RJ et al (2008) N-Myristoyltransferase: a prospective drug target for protozoan parasites. ChemMedChem 3:402-408
19. Brand S, Cleghorn LAT, McElroy SP et al (2012) Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med Chem 55:140-152
20. Bridges D, Gould MK, Nerima B et al (2007) Loss of the High Affinity Pentamidine Transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. Mol Pharmacol 71:1098-1108
21. Browning CH, Morgan GT, Robb JVM, Walls LP (1938) The trypanocidal action of certain phenanthridinium compounds. J Pathol Bacteriol 46:203
22. Bruce D (1895) Preliminary report on the tsetse fly disease or nagana, in Zululand. Harrison & Sons, London
23. Carter NS, Fairlamb AH (1993) Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361:173-176
24. Carter NS, Berger BJ, Fairlamb AH (1995) Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J Biol Chem 270:28153-28157
25. Chen YT, Lira R, Hansell E et al (2008) Synthesis of macrocyclic trypanosomal cysteine protease inhibitors. Bioorg Med Chem Lett 18:5860-5863
26. Clayton J (2010) Chagas disease: pushing through the pipeline. Nature 465:S12-S15
27. De Koning HP (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters. Implications for crossresistance with arsenicals. Mol Pharmacol 59:586-592
28. De Koning HP (2008) The ever-increasing complexities of arsenical-diamidine cross-resistance in African trypanosomes. Trends Parasitol 24:345-349
29. De Koning HP, Stewart M, Anderson L et al (2004) The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter; additional insights in diamidine resistance in African trypanosomes. Antimicrob Agents Chemother 48:1515-1519
30. De Koning HP, Gould MK, Sterk GJ et al (2012) Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets. J Infect Dis 206:229-237
31. Delespaux V, De Koning HP (2007) Drugs and drug resistance in African trypanosomiasis. Drug Resist Updat 10:30-50
32. Delespaux V, De Koning HP (2013) Transporters in antiparasitic drug development and resistance. In: Jäger T, Koch O, Flohé L (eds) Trypanosomatid diseases: molecular routes to drug discovery. Wiley-VCH, Weinheim, Germany, pp 335-350
33. Delespaux V, Chitanga S, Geysen D et al (2006) SSCP analysis of the P2 purine transporter TcoAT1 gene of Trypanosoma congolense leads to a simple PCR-RFLP test allowing the rapid identification of diminazene resistant stocks. Acta Trop 100:96-102
34. Delespaux V, Geysen D, Van den Bossche P, Geerts S (2008) Molecular tools for the rapid detection of drug resistance in animal trypanosomes. Trends Parasitol 245:236-242
35. Diaz-Gonzalez R, Kuhlmann FM, Galan-Rodriguez C et al (2011) The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing. PLoS Negl Trop Dis 5:e1297
36. Ding D, Zhao Y, Meng Q et al (2010) Discovery of novel benzoxaborole-based potent antitrypanosomal agents. ACS Med Chem Lett 1:165-169
37. Duggan AJ (1970) An historical perspective. In: Mulligan HW (ed) The African trypanosomiases. George Allen & Unwin, London, pp 41-88
38. Farazi TA, Waksman G, Gordon JI (2001) The biology and enzymology of protein Nmyristoylation. J Biol Chem 276:39501-39504
39. Fèvre EM, Coleman OG, Welburn SC, Maudlin I (2004) Reanalysing the 1900-1920 sleeping sickness epidemic in Uganda. Emerg Infect Dis 10:567573
40. Figarella K, Uzcategui NL, Zhou Y et al (2007) Biochemical characterization of Leishmania major aquaglyceroporin LmAQP1: possible role in volume regulation and osmotaxis. Mol Microbiol 65:1006-1017
41. Frearson JA, Brand S, McElroy SP et al (2010) N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464:728-732
42. Friedheim EA (1949) Mel B in the treatment of human trypanosomiasis. Am J Trop Med Hyg 29:173-180
43. Geerts S, Holmes PH, Eisler MC, Diall O (2001) African bovine trypanosomiasis: the problem of drug resistance. Trends Parasitol 17:25-28
44. Gorbal B, Sonuc N, Bhattacharjee H et al (2004) Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 279:31010-31017
45. Gould MK, De Koning HP (2011) Cyclic nucleotide signalling in protozoa. FEMS Microbiol Rev 35:515-541
46. Greenbaum DC, Mackey Z, Hansell E et al (2004) Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J Med Chem 47:3212-3219
47. Hua S, To WY, Nguyen TT et al (1996) Purification and characterization of proteasomes from Trypanosoma brucei. Mol Biochem Parasitol 78:33-46
48. Jackson AP, Allison HC, Barry JD et al (2013) A cell-surface phylome for African trypanosomes. PLoS Negl Trop Dis 7:e2121
49. Jacobs WA, Heidelberger M (1919) Aromatic arsenic compounds V. N-substituted glycylarsanilic acids. J Am Chem Soc 41:1809-1821
50. Jacobs RT, Nare B, Wring SA et al (2011) SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis. PLoS Negl Trop Dis 5:e1151
51. Jansen C, Wang H, Kooistra AJ et al (2013) Discovery of Novel Trypanosoma brucei Phosphodiesterase B1 Inhibitors by Virtual Screening against the Unliganded TbrPDEB1 Crystal Structure. J Med Chem 56:2087-2096
52. Jennings FW, Urquhart GM (1983) The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z Parasitenkd 69:577-581
53. Jennings FW, Atouguia JM, Murray M (1996) Topical chemotherapy for experimental murine African CNS-trypanosomiasis: the successful use of the arsenical, melarsoprol, combined with the 5-nitroimidazoles, fexinidazole or MK-436. Trop Med Int Health 1:590-598
54. Kaiser M, Bray MA, Cal M et al (2011) Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother 55:5602-5608
55. Kaminsky R, Mäser P (2000) Drug resistance in African trypanosomes. Curr Opin Anti-infect Investig Drugs 2:76-82
56. Kathiravan MK, Salake AB, Chothe AS et al (2012) The biology and chemistry of antifungal agents: a review. Bioorg Med Chem 20:5678-5698
57. Keiser J, Ericsson O, Burri C (2000) Investigations of the metabolites of the trypanocidal drug melarsoprol. Clin Pharmacol Ther 67:478-488
58. Kuepfer I, Schmid C, Allan M et al (2012) Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage rhodesiense sleeping sickness. PLoS Negl Trop Dis 6:e1695
59. Kunz S, Beavo JA, DAngelo MA et al (2006) Cyclic nucleotide specific phosphodiesterases of the kinetoplastida: a unified nomenclature. Mol Biochem Parasitol 145:133-135
60. Lanteri CA, Tidwell RR, Meshnick SR (2008) The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei. Antimicrob Agents Chemother 52:875-882
61. Legros D, Evans S, Maiso F et al (1999) Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 93:439-442
62. Lepesheva GI, Waterman MR (2007) Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim Biophys Acta 1770:467-477
63. Lepesheva GI, Ott RD, Hargrove TY et al (2007) Sterol 14α-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chem Biol 14:1283-1293
64. Lepesheva GI, Hargrove TY, Kleshchenko Y, Nes WD, Villalta F, Waterman MR (2008) CYP51: a major drug target in the cytochrome P450 superfamily. Lipids 43:1117-1125
65. Lepesheva GI, Hargrove TY, Anderson S et al (2010a) Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem 285:25582-25590
66. Lepesheva GI, Park HW, Hargrove TY et al (2010b) Crystal structures of Trypanosoma brucei sterol 14α-demethylase and implications for selective treatment of human infections. J Biol Chem 285:1773-1780
67. Lepesheva GI, Villalta F, Waterman MR (2011) Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). Adv Parasitol 75:65-87
68. Leslie M (2011) Drug developers finally take aim at a neglected disease. Science 333:933-935
69. Li H, Chen H, Steinbronn C et al (2011) Enhancement of proton conductance by mutations of the selectivity filter of aquaporin-1. J Mol Biol 407:607-620
70. Loftsson T, Duchene D (2007) Cyclodextrins and their pharmaceutical applications. Int J Pharm 329:1-11
71. Lourie EM, Yorke W (1937) Studies in Chemotherapy XVI: the trypanocidal action of synthalin. Ann Trop Med Parasitol 31:435-445
72. Mackey ZB, O'Brien TC, Greenbaum DC et al (2004) A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei. J Biol Chem 279:48426-48433
73. Mackey ZB, Koupparis K, Nishino M, McKerrow JH (2011) High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei. Chem Biol Drug Des 78:454-463
74. Mallari JP, Shelat AA, Obrien T et al (2008) Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J Med Chem 51:545-552
75. Mallari JP, Shelat AA, Kosinski A et al (2009) Structure-guided development of selective TbcatB inhibitors. J Med Chem 52:6489-6493
76. Mallari JP, Zhu F, Lemoff A et al (2010) Optimization of purine-nitrile TbcatB inhibitors for use in vivo and evaluation of efficacy in murine models. Bioorg Med Chem 18:8302-8309
77. Mäser P, Sütterlin C, Kralli A, Kaminsky R (1999) A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285:242-244
78. Mäser P, Wittlin S, Rottman M et al (2012) Antiparasitic agents: new drugs on the horizon. Curr Opin Pharmacol 12:562-566
79. Matovu E, Stewart M, Geiser F et al (2003) The mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot Cell 2:1003-1008
80. Mdachi RE, Thuita JK, Kagira JM et al (2009) Efficacy of the novel diamidine compound 2,5-Bis (4-amidinophenyl)- furan-bis-O-Methlylamidoxime (Pafuramidine, DB289) against Trypanosoma brucei rhodesiense infection in vervet monkeys after oral administration. Antimicrob Agents Chemother 53:953-957
81. Mercer L, Bowling T, Perales J et al (2011) 2,4-Diaminopyrimidines as potent inhibitors of Trypanosoma brucei and identification of molecular targets by a chemical proteomics approach. PLoS Negl Trop Dis 5:e956
82. Mills E, Price HP, Johner A et al (2007) Kinetoplastid PPEF phosphatases: dual acylated proteins expressed in the endomembrane system of Leishmania. Mol Biochem Parasitol 152:22-34
83. Morty RE, Troeberg L, Pike RN et al (1998) A trypanosome oligopeptidase as a target for the trypanocidal agents pentamidine, diminazene and suramin. FEBS Lett 433:251-256
84. Morty RE, Lonsdale-Eccles JD, Morehead J et al (1999) Oligopeptidase B from Trypanosoma brucei, a new member of an emerging subgroup of serine oligopeptidases. J Biol Chem 274:26149-26156
85. Morty RE, Troeberg L, Powers JC et al (2000) Characterisation of the antitrypanosomal activity of peptidyl alpha-aminoalkyl phosphonate diphenyl esters. Biochem Pharmacol 60:1497-1504
86. Morty RE, Lonsdale-Eccles JD, Mentele R et al (2001) Trypanosome-derived oligopeptidase B is released into the plasma of infected rodents, where it persists and retains full catalytic activity. Infect Immun 69:2757-2761
87. Munday JC, Rojas López KE, Eze AA et al (2013) Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptake. Int J Parasitol Drugs Drug Resist 3:69-76
88. Muyldermans S (2001) Single domain camel antibodies: current status. J Biotechnol 74:277-302
89. Nare B, Wring S, Bacchi C et al (2010) Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system African trypanosomiasis. Antimicrob Agents Chemother 54:4379-4388
90. Nguyen VK, Desmyter A, Muyldermans S (2001) Functional heavy-chain antibodies in Camelidae. Adv Immunol 79:261-296
91. O'Brien TC, Mackey ZB, Fetter RD et al (2008) A parasite cysteine protease is key to host protein degradation and iron acquisition. J Biol Chem 283:28934-28943
92. Oberholzer M, Marti G, Baresic M et al (2007) The Trypanosoma brucei cAMP phosphodiesterases TbrPDEB1 and TbrPDEB2: flagellar enzymes that are essential for parasite virulence. FASEB J 21:720-731
93. Ochiana SO, Gustafson A, Bland ND et al (2012) Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs. Bioorg Med Chem Lett 22:2582-2584
94. Oduor RO, Ojo KK, Williams GP et al (2011) Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads. PLoS Negl Trop Dis 5:e1017
95. Ojo KK, Gillespie JR, Riechers AJ et al (2008) Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother 52:3710-3717
96. Olego-Fernandez S, Vaughan S, Shaw MK et al (2009) Cell morphogenesis of Trypanosoma brucei requires the paralogous, differentially expressed calpain-related proteins CAP5.5 and CAP5.5V. Protist 160:576-590
97. Orrling KM, Jansen C, Vu XL et al (2012) Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1. J Med Chem 55:8745-8756
98. Paine MF, Wang M, Boykin D et al (2010) Diamidines for human African trypanosomiasis. Curr Opin Investig Drugs 11:876-883
99. Parsons M, Worthey EA, Ward PN, Mottram JC (2005) Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics 6:127
100. Pépin J, Milord F, Meurice F et al (1992) High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 86:254-256
101. Perales JB, Freeman J, Bacchi CJ et al (2011) SAR of 2-amino and 2,4-diamino pyrimidines with in vivo efficacy against Trypanosoma brucei. Bioorg Med Chem Lett 21:2816-2819
102. Phillips MA, Wang CC (1987) A Trypanosoma brucei mutant resistant to alphadifluoromethylornithine. Mol Biochem Parasitol 22:9-17
103. Price HP, Menon MR, Panethymitaki C et al (2003) Myristoyl-CoA:protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites. J Biol Chem 278:7206-7214
104. Price HP, Panethymitaki C, Goulding D, Smith DF (2005) Functional analysis of TbARL1, an Nmyristoylated Golgi protein essential for viability in bloodstream trypanosomes. J Cell Sci 118:831-841
105. Price HP, Stark M, Smith DF (2007) Trypanosoma brucei ARF1 plays a central role in endocytosis and Golgi-lysosome trafficking. Mol Biol Cell 18:864-873
106. Price HP, Guther ML, Ferguson MA, Smith DF (2010) Myristoyl-CoA:protein N-myristoyltransferase depletion in trypanosomes causes avirulence and endocytic defects. Mol Biochem Parasitol 169:55-58
107. Qiao Z, Wang Q, Zhang F et al (2012) Chalcone-benzoxaborole hybrid molecules as potent antitrypanosomal agents. J Med Chem 12:3553-3557
108. Robays J, Nyamowala G, Sese C et al (2008) High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis 14:966-967
109. Roberts CW, McLeod R, Rice DW et al (2003) Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 126:129-142
110. Rodgers J, Jones A, Gibaud S et al (2011) Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. PLoS Negl Trop Dis 5:e1308
111. Schlitzer M (2009) Wirkstoffe zur Behandlung der Afrikanischen Schlafkrankheit. Im letzten Jahrhundert entwickelt. Pharm Unserer Zeit 6:552-558
112. Schumann Burkard G, Jutzi P, Roditi I (2011) Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. Mol Biochem Parasitol 175:91-94
113. Scory S, Caffrey CR, Stierhof YD et al (1999) Trypanosoma brucei: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-phe-ala-CHN2. Exp Parasitol 91:327-333
114. Scory S, Stierhof YD, Caffrey CR, Steverding D (2007) The cysteine proteinase inhibitor Z-Phe-Ala-CHN2 alters cell morphology and cell division activity of Trypanosoma brucei bloodstream forms in vivo. Kinetoplastid Biol Dis 6:2
115. Scott AG, Tait A, Turner CM (1997) Trypanosoma brucei: lack of cross-resistance to melarsoprol in vitro by cymelarsan-resistant parasites. Exp Parasitol 86:181-190
116. Seebeck T, Sterk GJ, Ke H (2011) Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite. Future Med Chem 3:1289-1306
117. Shakur Y, De Koning HP, Ke H et al (2011) Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases. Handb Exp Pharmacol 204:487-510
118. Singh N, Kumar M, Singh RK (2012) Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med 5:485-497
119. Sokolova AY, Wyllie S, Patterson S et al (2010) Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob Agents Chemother 54:2893-2900
120. Steverding D (2010) The development of drugs for treatment of sleeping sickness: a historical review. Parasit Vectors 3:15
121. Steverding D, Spackman RW, Royle HJ, Glenn RJ (2005) Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors. Parasitol Res 95:73-76
122. Steverding D, Baldisserotto A, Wang X, Marastoni M (2011) Trypanocidal activity of peptidyl vinyl ester derivatives selective for inhibition of mammalian proteasome trypsin-like activity. Exp Parasitol 128:444-447
123. Stijlemans B, Conrath K, Cortez-Retamozo V et al (2004) Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 279:1256-1261
124. Torreele E, Bourdin Trunz B, Tweats D et al (2010) Fexinidazole - a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 4:e923
125. Troeberg L, Chen X, Flaherty TM et al (2000) Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei. Mol Med 6:660-669
126. Tsukaguchi H, Meremowicz S, Morton CC, Hediger MA (1999) Fuctional and molecular characterization of the human neutral solute channel aquaporin-9. Am J Physiol 277:F685-F696
127. Tweats D, Bourdin Trunz B, Torreele E (2012) Genotoxicity profile of fexinidazole-4√a drug candidate in clinical development for human African trypanomiasis (sleeping sickness). Mutagenesis 27:523-532
128. Unciti-Broceta JD, Maceira J, Morales S et al (2013) Nicotinamide inhibits the lysosomal cathepsin b-like protease and kills African trypanosomes. J Biol Chem 288:10548-10557
129. Urbaniak MD, Mathieson T, Bantscheff M et al (2012) Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei. ACS Chem Biol 7:1858-1865
130. Urbina JA (2013) Ergosterol biosynthesis for the specific treatment of Chagas disease: from basic science to clinical trials. In: Jäger T, Koch O, Flohé L (eds) Trypanosomatid diseases: molecular routes to drug discovery. Wiley-VCH, Weinheim, Germany, pp 489-514
131. Uzcategui NL, Szallies A, Pavlovic-Djuranovic S et al (2004) Cloning, heterologous expression, and characterization of three aquaglyceroporins from Trypanosoma brucei. J Biol Chem 279:42669-42676
132. Vermelho AB, Giovanni-de-Simone S, d'Avila-Levy CM et al (2007) Trypanosomatidae peptidases: a target for drugs development. Curr Enzym Inhib 3:19-48
133. Vincent IM, Creek D, Watson DG et al (2010) A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog 6:e1001204
134. Wang CC, Bozdech Z, Liu CL et al (2003) Biochemical analysis of the 20 S proteasome of Trypanosoma brucei. J Biol Chem 278:15800-15808
135. Wang H, Yan Z, Geng J et al (2007) Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors. Mol Microbiol 66:1029-1038
136. Wang C, Ashton TD, Gustafson A et al (2012a) Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 1. Sildenafil analogs. Bioorg Med Chem Lett 22:2579-2581
137. Wang H, Kunz S, Chen G et al (2012b) Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors. J Biol Chem 287:11788-11797
138. Watkins TI, Woolfe G (1952) Effect of changing the quaternizing group on the trypanocidal activity of dimidium bromide. Nature 169:506
139. Wenzler T, Boykin DW, Ismail MA et al (2009) New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289. Antimicrob Agents Chemother 53:4185-4192
140. Williams RA, Tetley L, Mottram JC, Coombs GH (2006) Cysteine peptidases CPA and CPB are vital for autophagy and differentiation in Leishmania mexicana. Mol Microbiol 61:655-674
141. Williamson J (1970) Review of chemotherapeutic and chemoprophylactic agents. In: Mulligan HW (ed) The African trypanosomiases. George Allen & Unwin, London, pp 125-221
142. Wragg WR, Washbourne K, Brown KN, Hill J (1958) Metamidium: a new trypanocidal drug. Nature 182:1005-1006
143. Yun O, Priotto GG, Tong J et al (2010) NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 4:e720
144. Zeuthen T, Wu B, Pavlovic-Djuranovic S et al (2006) Ammonia permeability of the aquaglyceroporins from Plasmodium falciparum, Toxoplasma gondii and Trypansoma brucei. Mol Microbiol 61:1598-1608
145. Zoraghi R, Seebeck T (2002) The cAMP-specific phosphodiesterase TbPDE2C is an essential enzyme in bloodstream form Trypanosoma brucei. Proc Natl Acad Sci USA 99:4343-4348